Study of Clinical Observation and Mechanism of Conbercept Combined with Dexamethasone Intravitreal Implant in the Treatment of Refractory Macular Edema

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600124921

Enrollment

Unknown

Registered

2026-05-19

Start date

2025-11-19

Completion date

Unknown

Last updated

2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Macular Edema

Interventions

Combination therapy group:Conbercept+Dexamethasone

monotherapy group:Conbercept

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic criteria for refractory macular edema, with poor response to >= 3 anti VEGF monotherapy treatments and central retinal thickness (CMT>300 µ m) in patients; 2. Age range: 18 to 75 years old; 3. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. There are other serious eye diseases such as eye infections and retinal detachment. 2. Allergic to Conbercept or Opdivo. 3. Severe systemic diseases cannot tolerate treatment.

Design outcomes

Primary

Measure	Time frame
Best corrected visual acuity (BCVA);macular fovea retinal thickness (CMT);	—

Secondary

Measure	Time frame
intraocular pressure;Inflammatory cytokine levels;	—

Countries

China

Contacts

Public ContactZhou Xuemei

Shenzhen University General Hospital

emily1979zxm@126.com+86 755 21839999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026